Campbell & CO Investment Adviser LLC Argenx Se Transaction History

Campbell & CO Investment Adviser LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$360.14 - $422.58 $1.13 Million - $1.33 Million	-3,143 Reduced 78.56%	858 $334,000
Q1 2023 May 11, 2023	BUY	$334.23 - $403.65 $135,697 - $163,881	406 Added 11.29%	4,001 $1.49 Million
Q4 2022 Feb 14, 2023	SELL	$342.17 - $402.31 $285,369 - $335,526	-834 Reduced 18.83%	3,595 $1.36 Million
Q3 2022 Nov 14, 2022	BUY	$343.2 - $395.75 $1.03 Million - $1.19 Million	3,001 Added 210.15%	4,429 $1.56 Million
Q2 2022 Aug 09, 2022	SELL	$269.58 - $378.88 $245,048 - $344,401	-909 Reduced 38.9%	1,428 $541,000
Q1 2022 May 09, 2022	BUY	$254.45 - $351.06 $136,639 - $188,519	537 Added 29.83%	2,337 $737,000
Q4 2021 Feb 10, 2022	BUY	$272.01 - $353.03 $136,005 - $176,515	500 Added 38.46%	1,800 $630,000
Q3 2021 Nov 10, 2021	BUY	$295.0 - $350.58 $383,500 - $455,754	1,300 New	1,300 $393,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Campbell & CO Investment Adviser LLC, based on Form 13F filings with the SEC.

Stay updated on Campbell & CO Investment Adviser LLC with notifications on news.